Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacy

作者
Tyler C. Detomasi,Gilles Degotte,Sijie Huang,Rahul K. Suryawanshi,Amy Diallo,Luca Lizzadro,Francisco José Zapatero Belinchón,Taha Y. Taha,Jiapeng Li,Alicia Richards,Eric R. Hantz,Zain Alam,Mauricio Montaño,Maria McCavitt-Malvido,Rajesh Gumpena,James R. Partridge,G.J. Correy,Yusuke Matsui,Annemarie F. Charvat,Isabella Glenn
出处
期刊:Science Advances [American Association for the Advancement of Science]
卷期号:11 (17): eadt7836-eadt7836 被引量:16
标识
DOI:10.1126/sciadv.adt7836
摘要

Abstract The main protease (M Pro ) of SARS-CoV-2 is crucial for viral replication and is the target of nirmatrelvir (the active ingredient of Paxlovid) and ensitrelvir. The identification of new agents with differentiated pharmacokinetic and drug resistance profiles will increase therapeutic options for COVID-19 patients and bolster pandemic preparedness generally. Starting with a lead-like dihydrouracil chemotype from a large-library docking campaign, we improved M Pro inhibition >1,000-fold by engaging additional sub-sites in the M Pro active site, most notably by employing a latent propargyl electrophile to engage the catalytic Cys145. Advanced leads from this series, including AVI-4516 and AVI-4773 show pan-coronavirus antiviral activity in cells, very low clearance in mice, and for AVI-4773 a rapid reduction in viral titers more than a million-fold after just three doses, more rapidly and effectively than the approved drugs, nirmatrelvir and ensitrelvir. Both AVI-4516 and AVI-477 3 are well distributed in mouse tissues, including brain, where concentrations ten or fifteen-thousand times the EC 90 , respectively, are observed eight hours after an oral dose. As exemplar of the series, AVI-4516 shows minimal inhibition of major CYP isoforms and human cysteine and serine proteases, likely due to its latent–electrophilic warhead. AVI-4516 also exhibits synergy in cellular infection models in combination with the RdRp inhibitor molnupiravir, while related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus in cells. The in vivo and antiviral properties of this new chemotype are differentiated from existing clinical and pre-clinical M Pro inhibitors, and will advance new therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses. One sentence summary This manuscript describes the discovery of a new class of potent inhibitors of the SARS-CoV-2 major proteases (M Pro ) with a unique mechanism of inhibition, pan coronaviral activity in cellulo , exquisite selectivity vs. the human proteome, and exceptional in vivo efficacy in SARS-CoV-2 infection models that surpasses that of currently approved agents.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
橘子味汽水完成签到,获得积分20
3秒前
羊羊羊发布了新的文献求助10
4秒前
4秒前
在水一方的应助被111采纳,获得10
5秒前
华仔的应助被DW采纳,获得10
7秒前
7秒前
充电宝的应助被史萌采纳,获得10
7秒前
SciGPT的应助被星辰采纳,获得10
8秒前
5007完成签到,获得积分10
8秒前
8秒前
9秒前
西麓麓发布了新的文献求助10
10秒前
所所的应助被白华苍松采纳,获得10
10秒前
10秒前
syvshc的应助被科研通管家采纳,获得10
11秒前
momo完成签到,获得积分10
11秒前
Hello的应助被科研通管家采纳,获得10
11秒前
科研大人完成签到,获得积分10
11秒前
羊羊羊完成签到,获得积分10
11秒前
无花果的应助被科研通管家采纳,获得10
11秒前
丘比特的应助被科研通管家采纳,获得10
11秒前
思源的应助被科研通管家采纳,获得10
11秒前
星辰大海的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
12秒前
12秒前
大模型的应助被科研通管家采纳,获得10
12秒前
情怀的应助被科研通管家采纳,获得10
12秒前
12秒前
852的应助被科研通管家采纳,获得10
12秒前
秋风的应助被科研通管家采纳,获得10
12秒前
wanci的应助被科研通管家采纳,获得10
12秒前
Scarlett的应助被科研通管家采纳,获得10
12秒前
赘婿的应助被科研通管家采纳,获得10
13秒前
Eau驳回了fantasy的应助
14秒前
某某完成签到,获得积分10
16秒前
Nole的应助被淡淡的小蜜蜂采纳,获得10
16秒前
月亮打烊完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196